SereNeuro Therapeutics

Baltimore, United States

pre-seedFreshly fundedBiotechDrug Discoverybiopharmaceuticals

◆ Stage

pre-seed

◆ Location

Baltimore, United States

◆ Links

Website ↗

◆ About SereNeuro Therapeutics

Preclinical-stage biotech developing non-opioid pain therapies using purified human pain-sensing neurons derived from induced pluripotent stem cells.

◆ What sets it apart

Its SN101 program uses purified, mature iPSC-derived human nociceptors designed to absorb inflammatory pain factors while potentially preserving joint tissue, rather than merely blocking pain signaling.[1][2]

◆ Sectors

BiotechDrug Discoverybiopharmaceuticalsneurologypain therapeutics

◆ Business

Modelhardware

CustomerPatients with chronic osteoarthritis and neuropathic pain, served through pharmaceutical and clinical-development channels

◆ Notable

Closed an oversubscribed pre-seed financing on October 5, 2026.[2]
Advanced lead program SN101 toward IND-enabling studies.[1][2]
Developed a second preclinical program, SN102, targeting trigeminal neuralgia and other neuropathic pain.[1][2]
Received a $399,575 Maryland Stem Cell Research Commission commercialization award.[7]

◆ Funding rounds

pre-seed

5 Oct 2026

Source ↗

◆ Explore the market

Biotech Drug Discovery Pre-Seed United States

◆ FAQ

What does SereNeuro Therapeutics do?

Preclinical-stage biotech developing non-opioid pain therapies using purified human pain-sensing neurons derived from induced pluripotent stem cells.

Where is SereNeuro Therapeutics based?

SereNeuro Therapeutics is based in Baltimore, United States.